Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.61 |
| ▸ | KLKB1 | P03952 | 9/20 | 0.59 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.58 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.57 |
| ▸ | NECTIN4 | Q96NY8 | 3/20 | 0.54 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.52 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.52 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.52 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.52 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.52 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.51 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30883974 | 0.81 | KLK5 (0.55) | CHRNA7KLK5 | |
| SCHEMBL29483659 | 0.81 | KLK5 (0.55) | CHRNA7KLK5 | |
| SCHEMBL23824135 | 0.79 | ACE2 (0.57) | KLKB1KLK5NECTIN4 | |
| SCHEMBL26935091 | 0.75 | PCSK9 (0.63) | KLKB1PCSK9KLK5 | |
| SCHEMBL26935089 | 0.75 | HDAC8 (0.57) | KLKB1PCSK9KLK5 | |
| Human Neutrophil Defensin 1 SCHEMBL29412280 | 0.75 | KLKB1 (0.67) | CHRNA7KLKB1KCNA3KCNA1 | |
| SCHEMBL29412265 | 0.74 | KLKB1 (0.63) | CHRNA7KLKB1KCNA3KCNA1 | |
| SCHEMBL24724808 | 0.73 | EPHA2 (0.57) | CHRNA7KLKB1PCSK9 | |
| SCHEMBL16431238 | 0.73 | OXTR (0.63) | — | |
| SCHEMBL19754419 | 0.73 | CD274 (0.81) | CHRNA7KLKB1PCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11357873-B2 | Chiral cyclen compounds and their uses | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2022-06-14 | — | — | US | disclosed |
| US-20210283278-A1 | CHIRAL CYCLEN COMPOUNDS AND THEIR USES | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11357873-B2 | Chiral cyclen compounds and their uses | DCTN3, DCTN1, CDK3 | CHRNA7 1475/4885KLKB1 4286/4885PCSK9 4800/4885 |
| US-20210283278-A1 | CHIRAL CYCLEN COMPOUNDS AND THEIR USES | DCTN3, DCTN1, CDK3 | CHRNA7 1475/4885KLKB1 4286/4885PCSK9 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.